Search research articles
Contact Us
Filters
Showing results (151-160 of 437) with videos related to
Page
of 44
Sort By:
Journal for Immunotherapy of Cancer
|
March 19, 2021
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
David Gandara, Martin Reck, Denis Moro-Sibilot, et al.
Oncology
|
January 25, 2012
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer
Johan Vansteenkiste, Rodryg Ramlau, Joachim von Pawel, et al.
Clinical Lung Cancer
|
March 26, 2017
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
Jordi Remon, Jessica Menis, Baktiar Hasan, et al.
Clinical Lung Cancer
|
October 10, 2006
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer
Wolfgang Schuette, Thomas Blankenburg, Claus-Peter Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2009
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
Martin Reck, Joachim von Pawel, Petr Zatloukal, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
August 2, 2022
Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography
Jens Vogel-Claussen, Florian Lasch, Benjamin-Alexander Bollmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2020
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer
Martin Reck, Alexander Luft, Igor Bondarenko, et al.
Clinical Lung Cancer
|
April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Makoto Nishio, Luis Paz-Ares, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
Thomas J Lynch, Igor Bondarenko, Alexander Luft, et al.
Nature Reviews. Clinical Oncology
|
October 9, 2025
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
Jordi Remon, Antonin Levy, Romane Gille, et al.
Page
of 44
Search research articles
Search
Showing results (151-160 of 437) with videos related to
Sort By:
Page
of 44
Journal for Immunotherapy of Cancer
|
March 19, 2021
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
David Gandara, Martin Reck, Denis Moro-Sibilot, et al.
Oncology
|
January 25, 2012
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer
Johan Vansteenkiste, Rodryg Ramlau, Joachim von Pawel, et al.
Clinical Lung Cancer
|
March 26, 2017
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
Jordi Remon, Jessica Menis, Baktiar Hasan, et al.
Clinical Lung Cancer
|
October 10, 2006
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer
Wolfgang Schuette, Thomas Blankenburg, Claus-Peter Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2009
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
Martin Reck, Joachim von Pawel, Petr Zatloukal, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
August 2, 2022
Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography
Jens Vogel-Claussen, Florian Lasch, Benjamin-Alexander Bollmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2020
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer
Martin Reck, Alexander Luft, Igor Bondarenko, et al.
Clinical Lung Cancer
|
April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Makoto Nishio, Luis Paz-Ares, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
Thomas J Lynch, Igor Bondarenko, Alexander Luft, et al.
Nature Reviews. Clinical Oncology
|
October 9, 2025
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
Jordi Remon, Antonin Levy, Romane Gille, et al.
Page
of 44